Abstract
We present a case series of seven patients with metastatic renal cell carcinoma treated with bevacizumab (10 mg/kg) in combination with sunitinib 25-50 mg as salvage therapy after disease progression under sunitinib monotherapy. Two patients had a partial response, four had stable disease, and one patient had disease progression. After a median follow-up of 17.2 mo, median progression-free survival and overall survival were 8.5 and 15.1 mo, respectively. Two patients experienced exacerbation of their preexisting hypertension; there were no grade 4 toxicities. The bevacizumab-sunitinib combination in sunitinib-refractory patients seems active and has a tolerable toxicity profile.
MeSH terms
-
Anorexia / chemically induced
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Asthenia / chemically induced
-
Bevacizumab
-
Bone Neoplasms / secondary
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / secondary*
-
Diarrhea / chemically induced
-
Disease Progression
-
Drug Resistance, Neoplasm
-
Female
-
Follow-Up Studies
-
Humans
-
Indoles / administration & dosage*
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / mortality
-
Kidney Neoplasms / pathology
-
Liver Neoplasms / secondary
-
Lymphatic Metastasis
-
Male
-
Middle Aged
-
Mucositis / chemically induced
-
Pancreatic Neoplasms / secondary
-
Pyrroles / administration & dosage*
-
Salvage Therapy / methods*
-
Sunitinib
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Indoles
-
Pyrroles
-
Bevacizumab
-
Sunitinib